Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback